

UNCLASSIFIED

RDT&E BUDGET ITEM JUSTIFICATION SHEET (R-2 Exhibit)								DATE February 2000	
APPROPRIATION/BUDGET ACTIVITY RDT&E/Defense Wide/BA 1							R-1 ITEM NOMENCLATURE Gulf War Illnesses Research PE 0601105D8Z		
COST(In Millions)	FY 1999	FY 2000	FY 2001	FY 2002	FY 2003	FY 2004	FY 2005	Cost to Complete	Total Cost
Total Program Element (PE) Cost	22.588	24.543	16.978	16.856	0.000	0.000	0.000	Continuing	Continuing
Gulf War Illnesses Research/P105	22.588	24.543	16.978	16.856	0.000	0.000	0.000	Continuing	Continuing

(U) **A. Mission Description and Budget Item Justification**

(U) **BRIEF DESCRIPTION OF ELEMENT**

(U)This program of Gulf War Illnesses (GWI)-related research addresses topics relevant to identifying the etiology and treatment of GWI, increasing our understanding of issues pertinent to Force Health Protection, and enhancing the protection of Service members against deployment-related health threats in future deployments. This program is conducted in coordination with the Research Working Group of the Persian Gulf Veterans' Coordinating Board.

UNCLASSIFIED

UNCLASSIFIED

RDT&E BUDGET ITEM JUSTIFICATION SHEET (R-2 Exhibit)							DATE February 2000	
APPROPRIATION/BUDGET ACTIVITY RDT&E/Defense Wide/BA 1							R-1 ITEM NOMENCLATURE Gulf War Illnesses Research PE 0601105D8Z	

COST(In Millions)	FY 1999	FY 2000	FY 2001	FY 2002	FY 2003	FY 2004	FY 2005	Cost to Complete	Total Cost
Total Program Element (PE) Cost	22.588	24.543	16.978	16.856	0.000	0.000	0.000	Continuing	Continuing
Gulf War Illnesses Research/P105	22.588	24.543	16.978	16.856	0.000	0.000	0.000	Continuing	Continuing

(U) **Project Number and Title: P105 Gulf War Illnesses Research**

(U) **PROGRAM ACCOMPLISHMENTS AND PLANS**

(U) **FY1999 Accomplishments:**

(U)In FY 1999, the Department of Defense developed an investment strategy and execution plan to pursue a balanced program of research related to the etiology and treatment of Gulf War Illnesses and to the protection of Service members in future deployments. Specific efforts include the following:

- (U)Competed and selected for funding projects directed to multidisciplinary research to elucidate neurobiology of stress, connecting psychosocial, psychophysiological, and somatic/physiological outcomes in models of nonspecific and undiagnosed symptoms typical of ill Gulf War veterans.
(\$ 4.600 Million)
- (U)Competed and selected for funding projects which advance deployment toxicology bioassay and biosentinel-based detection and exposure assessment methods, particularly strategies to assess neurotoxic health hazards.
(\$ 0.700 Million)
- (U)Competed and selected for funding projects that explore and establish fundamentally important interactions of medical materiel and operational environments, such as stress effects on access to the brain by prophylactic drugs, radio frequency radiation-enhanced toxicity of drugs, stress effects and interactions of multiple vaccines on vaccine effectiveness.
(\$ 3.100 Million)
- (U)Competed and selected for funding epidemiological studies to develop and evaluate effectiveness of health assessment and health care delivery pre-, during, and post-deployment, thus advancing Force Health Protection surveillance strategies in future deployments.
(\$ 1.800 Million)

UNCLASSIFIED

UNCLASSIFIED

RDT&E BUDGET ITEM JUSTIFICATION SHEET (R-2 Exhibit)		DATE February 2000
APPROPRIATION/BUDGET ACTIVITY RDT&E/Defense Wide/BA 1	R-1 ITEM NOMENCLATURE Gulf War Illnesses Research PE 0601105D8Z	

(U)Initiated a 2-year Medical Follow-up Agency (Institute of Medicine) study of Aberdeen personnel previously exposed to low level chemical agents.

(\$ 1.000 Million)

(U)Initiated a new basic research program to develop a Leishmania vaccine and demonstrate feasibility of reliable serological diagnostic tests in a 4-year program conducted by Army and Navy infectious disease research laboratories.

(\$ 1.500 Million)

(U)Initiated program to study antibodies to squalene, related to concerns about vaccine health risks.

(\$ 0.600 Million)

(U)Conducted epidemiological research to complete current Gulf War Illness cohort studies and initiate new efforts at the Naval Health Research Center involving deployment health assessments.

(\$ 1.500 Million)

(U)Competed and selected for funding a congressionally-mandated study of difficult-to-diagnose conditions such as fibromyalgia, chronic fatigue syndrome, and multiple chemical sensitivities, using advanced neuroscience methods.

(\$ 3.000 Million)

(U)Plan studies of DOD and VA Gulf War registry participants in unique opportunity to address hypothesis-driven epidemiological research on deployment health risk factors.

(\$ 1.000 Million)

(U) Provided program management, contract servicing, and supplemental funding to previously funded GWI research studies.

(\$ 3.788 Million)

(U) FY2000 Plans:

(U)Continue projects in neurobiology of stress, deployment toxicology methods, operational interactions of medical materiel, and force health protection epidemiology, and competitively fund new projects to address issues raised by emerging finding from existing research and other discoveries.

(\$ 11.967 Million)

(U)Initiate a 2-year Medical Follow-up Agency (Institute of Medicine) study of prewar healthcare-seeking behaviors of Gulf War veterans and their subsequent health outcomes.

(\$ 0.500 Million)

(U)Continue development of a Leishmania vaccine and demonstrate feasibility of reliable serological diagnostic tests in a four-year program conducted by Army and Navy infectious disease research laboratories.

UNCLASSIFIED

UNCLASSIFIED

RDT&E BUDGET ITEM JUSTIFICATION SHEET (R-2 Exhibit)		DATE
APPROPRIATION/BUDGET ACTIVITY		February 2000
RDT&E/Defense Wide/BA 1	R-1 ITEM NOMENCLATURE	
	Gulf War Illnesses Research	
	PE 0601105D8Z	

(\$1.500 million)

(U)Continue an expanded Tri-Service epidemiological research effort at the Naval Health Research Center involving deployment health assessments.

(\$ 1.750 Million)

(U)Initiate a program reported as a Defense Technology Objective on health behavior interventions research intended to develop and demonstrate efficacy of programs to enhance deployment readiness.

(\$ 2.000 Million)

(U)Provide program management, contract servicing, and supplemental funding to previously funded GWI research studies.

(\$ 6.826 Million)

(U) FY2001 Plans:

(U)Continue projects in neurobiology of stress, deployment toxicology methods, operational interactions of medical materiel, and force health protection epidemiology, and competitively fund new projects to address issues raised by emerging finding from existing research and other discoveries.

(\$ 10.000 Million)

(U)Continue program on Health Behaviors Interventions Research.

(\$ 2.000 Million)

(U)Continue development of a Leishmania vaccine and demonstrate feasibility of reliable serological diagnostic tests in a four-year program conducted by Army and Navy infectious disease research laboratories.

(\$ 1.500 Million)

(U)Continue an expanded Tri-Service epidemiological research effort at the Naval Health Research Center involving deployment health assessments.

(\$ 1.750 Million)

(U)Provide program management, contract servicing, and supplemental funding to previously funded GWI research studies.

(\$ 1.728 Million)

UNCLASSIFIED

UNCLASSIFIED

(U)	<u>B. Program Change Summary</u>	<u>FY1999</u>	<u>FY2000</u>	<u>FY2001</u>	<u>Total Cost</u>
	Previous President's Budget	23.674	19.185	19.098	Continuing
	Appropriated Value	0.000	25.185	0.000	Continuing
	Adjustments to Appropriated Value				
	a. Congressionally Directed Undistributed Reduction	0.000	0.000	0.000	
	b. Rescission/Below-threshold Reprogramming, Inflation Adjustment	(1.086)	(0.435)	(0.120)	
	c. Other	0.000	(0.207)	(2.000)	
	Current President's Budget	22.588	24.543	16.978	Continuing

Change Summary Explanation:

(U) **Funding:** FY 1999 establishes a separate PE for Gulf War Illness Research. Funding changes are due to programmatic reductions. FY 2000 reductions are due to inflation adjustments and government wide rescission. FY 2001 reductions are due to programmatic decisions and inflation reductions.

(U) **Schedule:** N/A

(U) **Technical:** N/A

(U) **C. OTHER PROGRAM FUNDING SUMMARY COST:** N/A

(U) **D. ACQUISITION STRATEGY:** N/A

(U) **E. SCHEDULE PROFILE:** N/A

UNCLASSIFIED